BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 9263357)

  • 21. [Hemostasis disorders and their treatment in patients with chronic myeloproliferative diseases].
    Sidorova LD; Arkhipov BF; Degtiareva MM; Barkagan LZ
    Ter Arkh; 1981; 53(9):91-5. PubMed ID: 7302866
    [No Abstract]   [Full Text] [Related]  

  • 22. Fertility, pregnancy and the management of myeloproliferative disorders.
    Griesshammer M; Bergmann L; Pearson T
    Baillieres Clin Haematol; 1998 Dec; 11(4):859-74. PubMed ID: 10640221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J; Kantarjian H
    Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
    van Genderen PJ; Leenknegt H; Michiels JJ
    Semin Thromb Hemost; 1997; 23(4):385-9. PubMed ID: 9263356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders.
    Emiliani C; Ciferri S; Mencarelli S; Mezzasoma AM; Momi S; Orlacchio A; Gresele P
    Platelets; 2006 Feb; 17(1):20-9. PubMed ID: 16308183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelets and thrombosis in myeloproliferative diseases.
    Harrison CN
    Hematology Am Soc Hematol Educ Program; 2005; ():409-15. PubMed ID: 16304412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
    Landolfi R; Cipriani MC; Novarese L
    Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombocytosis: too much of a good thing?
    Schafer AI
    Trans Am Clin Climatol Assoc; 2002; 113():68-76; discussion 76-7. PubMed ID: 12053719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bleeding and thrombosis in the myeloproliferative disorders.
    Schafer AI
    Blood; 1984 Jul; 64(1):1-12. PubMed ID: 6375757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
    Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
    Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
    Spivak JL
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):1-5. PubMed ID: 15190515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic myeloproliferative disorders.
    Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
    Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of bleeding and thrombosis in myeloproliferative disorders.
    Landolfi R; Marchioli R; Patrono C
    Thromb Haemost; 1997 Jul; 78(1):617-21. PubMed ID: 9198226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
    Ryningen A; Apelseth T; Hausken T; Bruserud Ø
    Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update on the platelet dysfunction in chronic myeloproliferative syndromes.
    Vlădăreanu AM; Ciufu C; Bumbea H; Onisâi M; Aramă S
    Rom J Intern Med; 2008; 46(1):9-15. PubMed ID: 19157266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.